22:46 , Oct 19, 2018 |  BioCentury  |  Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...
23:05 , Oct 5, 2018 |  BioCentury  |  Finance

Risk-sharing at scale

By operating under the Blackstone umbrella, Clarus Ventures will be able to significantly scale up its risk-sharing investment strategy. On Oct. 4, private equity firm Blackstone announced plans to acquire Clarus for undisclosed terms. Clarus co-founder...
20:17 , Oct 5, 2018 |  BC Week In Review  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
20:14 , Oct 4, 2018 |  BC Extra  |  Company News

Blackstone acquiring Clarus; Galakatos to lead PE firm's new life sciences unit

Blackstone (NYSE:BX) will acquire life sciences investment firm Clarus and launch a new unit, Blackstone Life Sciences. Clarus co-founder and Managing Director Nick Galakatos, who will lead the unit, told BioCentury the group intends to...
16:42 , Sep 19, 2018 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A heterocycloalkynylbenzimide-based dual DDR1/DDR2 inhibitor could be used to probe the role of two proteins in inflammatory diseases. Chemical synthesis and in vitro activity assays of heterocycloalkynylbenzimide analogs identified a compound that...
22:07 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other molecule...
18:07 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Novo's REPAIR fund makes first investment in Swiss antibiotic company

Novo Holdings A/S invested CHF6.8 million ($7 million) on Sept. 6 into antibiotic company Polyphor Ltd. (SIX:POLN) through the purchase of 178,947 new shares at CHF38. The funds come from Novo's REPAIR Impact Fund, which...
18:11 , Aug 30, 2018 |  BC Innovations  |  Translation in Brief

Turning off the inflammasome

In a July Nature paper, a team from the University of California San Diego identified CMPK2 as a potential target for inflammatory diseases involving NLRP3 inflammasomes and may launch a spinout to develop the findings....
17:50 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest monocytes treated with LPS could help prevent ischemic brain injury. In a mouse model of ischemic brain injury, adoptive transfer of monocytes from LPS-treated donor mice decreased infarct size compared...
03:33 , Aug 17, 2018 |  BC Week In Review  |  Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of 2 million shares at $13 in an IPO on NASDAQ. Cantor Fitzgerald, Maxim Group, Laidlaw, Northland Securities...